Melola Discovery

← Melola Discovery

Journal SINTA 1

Review Article and Clinical Experience METABOLIC SYNDROME VS INSULIN RESISTANCE SYNDROME (A CLUSTER OF COMPONENTS AND STRATEGIES FOR TREATMENT)

Folia Medica Indonesiana · Vol. 41 No. 1 (2005)

ISSN
2355-8393, 2599-056X
Published
2005-01-01
Publisher
Airlangga University
Language
en

Abstract

Metabolic Syndrome = MS (in which abdominal Obesity is the culprit of the MS) is defined by NCEP-ATP III in 2001, whereas Dysmetabolic Syndrome = DMS and Insulin Resistance Syndrome = IRS are recommended terms by AACE (in 2002) and ACE (in 2002), respectively. Both AACE and ACE stated that insulin resistance plays central role in the syndrome. All these terms of the syndrome are originally and firstly coined by Reaven as Syndrome-X in 1988, and then Metabolic Syndrome-X in 1999. Either MS or DMS or IRS has become major issues because of its impact on the risks of Type 2 DM (T2DM) development and cardiovascular diseases. The criteria of MS, IRS (including its risk factors), and the clusters of components belong to MS and IRS, are listed in this paper. Rational strategies for the treatment of MS and IRS are focused on obesity and insulin resistance, respectively, and can be summarized as follows A. Improving insulin sensitivity and lifestyle (weight loss 5-10%, aerobic exercise ± 30-40 min, 4 times/week). B. Pharmacological Interventions directed to the targets for (mmHg, ml/dl) Blood Pressure 40 for men, and > 50 for women. Clinical evidence-based data supported, that Metformin (UKPDS Outcomes), Sibutramine (STORM Landmark Trial), and Orlistat (XENDOS Study), to date, are the promising drugs for the treatment of MS/IRS. However, the drugs specifically to improve the insulin sensitivity are hoped to treat this Syndrome. Conclusions Syndrome-X, Metabolic Syndrome-X, MS, DMS, or IRS, all have become major issues because of their roles in the development of either T2DM or Cardiovascular Diseases. The cluster of components of this Syndrome and its risk factors should be well recognized. Improving insulin sensitivity, losing body weight, aerobic exercise, and pharmacologic interventions (Metformin, Sibutramin, Orlistat) are rational strategies for the treatment of MS/IRS.

Keywords

Collaboration network of the authors

8 authors · 16 co-authorship links · 7 across different organisations

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Universitas Airlangga
  • University of Brawijaya
  • Rumah Sakit Umum Pusat Dr. Sardjito
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Agung Sindu PranotoUniversitas Airlangga1
Hermina NovidaUniversitas Airlangga1
Jongky Hendro PrayitnoAffiliation unknown1
Adeodatus Yuda HandayaRumah Sakit Umum Pusat Dr. Sardjito1
Djanggan SargowoUniversity of Brawijaya1
Diana LyrawatiUniversity of Brawijaya1
Mohammad Aris WidodoUniversity of Brawijaya1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, first harvested 19 Nov 2026, last seen 19 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Review Article and Clinical Experience METABOLIC SYNDROME VS INSULIN RESISTANCE SYNDROME (A CLUSTER OF COMPONENTS AND STRATEGIES FOR TREATMENT)</dc:title><dc:creator>Askandar Tjokroprawiro</dc:creator><dc:subject>metabolic syndrome</dc:subject><dc:subject>dysmetabolic syndrome</dc:subject><dc:subject>abdominal obesity</dc:subject><dc:subject>insulin resistance</dc:subject><dc:subject>type 2 diabetes</dc:subject><dc:subject>cardiovascular risk</dc:subject><dc:subject>insulin sensitivity</dc:subject><dc:subject>weight loss</dc:subject><dc:subject>aerobic exercise</dc:subject><dc:subject>metformin</dc:subject><dc:subject>sibutramine</dc:subject><dc:subject>orlistat</dc:subject><dc:subject>NCEP ATP III criteria</dc:subject><dc:description xml:lang="en">Metabolic Syndrome = MS (in which abdominal Obesity is the culprit of the MS) is defined by NCEP-ATP III in 2001, whereas Dysmetabolic Syndrome = DMS and Insulin Resistance Syndrome = IRS are recommended terms by AACE (in 2002) and ACE (in 2002), respectively. Both AACE and ACE stated that insulin resistance plays central role in the syndrome. All these terms of the syndrome are originally and firstly coined by Reaven as Syndrome-X in 1988, and then Metabolic Syndrome-X in 1999. Either MS or DMS or IRS has become major issues because of its impact on the risks of Type 2 DM (T2DM) development and cardiovascular diseases. The criteria of MS, IRS (including its risk factors), and the clusters of components belong to MS and IRS, are listed in this paper. Rational strategies for the treatment of MS and IRS are focused on obesity and insulin resistance, respectively, and can be summarized as follows A. Improving insulin sensitivity and lifestyle (weight loss 5-10%, aerobic exercise ± 30-40 min, 4 times/week). B. Pharmacological Interventions directed to the targets for (mmHg, ml/dl) Blood Pressure 40 for men, and &gt; 50 for women. Clinical evidence-based data supported, that Metformin (UKPDS Outcomes), Sibutramine (STORM Landmark Trial), and Orlistat (XENDOS Study), to date, are the promising drugs for the treatment of MS/IRS. However, the drugs specifically to improve the insulin sensitivity are hoped to treat this Syndrome. Conclusions Syndrome-X, Metabolic Syndrome-X, MS, DMS, or IRS, all have become major issues because of their roles in the development of either T2DM or Cardiovascular Diseases. The cluster of components of this Syndrome and its risk factors should be well recognized. Improving insulin sensitivity, losing body weight, aerobic exercise, and pharmacologic interventions (Metformin, Sibutramin, Orlistat) are rational strategies for the treatment of MS/IRS.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2005-01-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>http://journal.unair.ac.id/filerPDF/Ask%200403.pdf</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 41 No 1 (2005)</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language></oai_dc:dc>